A NOVEL LINK BETWEEN ADIPOKINES AND LIPOPROTEIN (A) TO CONTEMPLATE THEIR DIAGNOSTIC ROLE IN PATIENTS WITH STEMI AND NSTEMI
AbstractBackground: Early detection of cardiac events allow better and cost-effective triage and well-timed management of these patients. Study was conducted to evaluate the prognostic significance of plasma adiponectin, resistin and lipoprotein (a) in a group of patients with ST segment elevation myocardial infarction and non-ST-segment elevation myocardial infarction. These parameters were also compared with other predictors like troponin T, troponin I and CK-MB. Methods: Present study was based on the 100 patients with AMI of whom 52 had a diagnosis of STEMI, and 48 had NSTEMI. Duration of study was January to June 2015. Patients having chest pain that was indicative of myocardial ischemia within first 12 hours after the onset of symptoms were included in the study. Adiponectin, Lp (a), resistin, troponin T and troponin I were estimated using ELISA method. Level of CK-MB was measured by Auto-analyser using standard kit of Merck. Results: Mean age of patients with STEMI was 52.32 years and with NSTEMI it was 48.17 years. Mean value of BMI of patients with STEMI was 28.33 and with NSTEMI was 25.22 Kg/m2. Duration of chest pain in patients with STEMI was 8.64 and patients with NSTEMI it was 16.52hours with highly significant difference (p<0.001). History of smoking in patients with STEMI was more as compared to the patients with NSTEMI. Level of CPK, adiponectin and lipoprotein (a) was raised in patients with STEMI as compared to patients with NSTEMI but significant difference was only found in levels of CPK (p<0.001) and in adiponectin (p<0.05). Level of serum CK-MB, TnT, TnI and resistin was raised in patients with NSTEMI as compared to patients with STEMI but significant difference (p<0.001) was only observed in serum troponin I concentration. Conclusion: It is concluded that the incidence of STEMI and NSTEMI is similar in our patients. However, the markers of STEMI are increased level of adiponectin and Lp(a) and the markers of NSTEMI are troponins especially troponin I, resistin and CKMB.Keywords: Cardiac markers; STEMI; NSTEMI, Adipokines, Lipoprotein
Loria V, Leo M, Biasillo G, Dato I, Biasucci LM. Biomarkers in Acute Coronary Syndrome. Biomark Insights 2008;3:453–68.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update. a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119(3):e21–182.
Witassek F, Schwenkglenks M, Erne P, Radovanovic D. Impact of Body Mass Index on mortality in Swiss hospital patients with ST-elevation myocardial infarction: does an obesity paradox exist? Swiss Med Wkly 2014;144:w13986.
Kontos MC, Diercks DB, Kirk JD. Emergency Department and Office-Based Evaluation of Patients with chest Pain. Mayo Clin Proc 2010;85(3):284–99.
Zdzienicka J, Siudak Z, Zawiślak B, Dziewierz A, Rakowski T, Dubiel J, et al. Patients with non-ST-elevation myocardial infarction and without chest pain are treated less aggressively and experience higher in-hospital mortality. Kardiol Pol 2007;65(7):769–7.
Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Houchman JS, et al. ACC/AHA Guidelines for the Management of Patients With Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction: Executive Summary and Recommendations. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable. Circulation 2000;102(10):1193–1209.
Peterson ED, Roe MT, Chen AY, Fonarow GC, Lytle BL, Cannon CP, et al. The NCDR ACTION Registry-GWTG: transforming contemporary acute myocardial infarction clinical care. Heart 2010;96(22):1798–1802.
Wienbergen H, Gitt AK, Juenger C, Schiele R, Heer T, Towae F, et al. Impact of the body mass index on occurrence and outcome of acute ST-elevation myocardial infarction. Clin Res Cardiol 2008;97(2):83–8.
Herrmann J, Gersh BJ, Goldfinger JZ, Witzenbichler B, Guagliumi G, Dudek D, Kornowski R, et al. Body mass index and acute and long-term outcomes after acute myocardial infarction (from the Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction Trial). Am J Cardiol 2014;114(1):9–16.
Lazzeri C, Valente S, Chiostri M, Attanà P, Picariello C, SoriniDini C, et al. Impact of age on the prognostic value of body mass index in ST-Elevation myocardial infarction. Nutr Metab Cardiovasc Dis 2013;23(3):205–11.
O’Brien EC, Fosbol EL, Peng SA, Alexander KP, Roe MT, Peterson ED. Association of body mass index and long-term outcomes in older patients with non-ST-segment-elevation myocardial infarction: results from the CRUSADE Registry. Circ Cardiovasc Qual Outcomes 2014;7(1):102–9.
Morrow DA, Cannon CP, Rifai N, Frey MJ, Vicari R, Lakkis N, et al. Ability of minor elevations of troponin I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial. JAMA 2001;286(19):2405–12.
AL-Otaiby M, AlAmri HS, Al-Moghairi AM. The clinical significance of cardiac troponins in medical practice. J Saudi Heart Assoc 2011;23(1):3–11.
Labugger R, Organ L, Collier C, Atar D, Van Eyk JE. Extensive troponin I and T modification detected in serum from patients with acute myocardial infarction. Circulation 2000;102(11):1221–6.
McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, et al. Ninety-minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104(13):1483–8.
Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. J Am Coll Cardiol 2007;50(7):e1–157.
Kavsak PA, MacRae AR, Newman AM, Lustig V, Palomaki GE, Ko DT, et al. Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. Clin Chim Acta 2007;380(1-2):213–6.
Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infection. Circulation 2008;117(2):296–329.
Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009;54(23):2205–41.
Erer HB, Sayar N, Guvenc TS, Aksaray S, Yilmaz H, Altay S, et al. Prognostic value of serum resistin levels in patients with acute myocardial infarction. Kardiol Pol 2014;72(2):181–6.
Kusminski CM, da Silva NF, Creely SJ, Fisher FM, Harte AL, Baker AR, et al. The in vitro effects of resistin on the innate immune signaling pathway in isolated human subcutaneous adipocytes. J Clin Endocrinol Metab 2007;92(1):270–6.
Lubos E, Messow CM, Schnabel R, Rupprecht HJ, Espinola-Klein C, Bickel C, et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis 2007;193(1):121–8.
Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, et al. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb 1993;13(6):826–33.
Gouni-Berthold I, Berthold HK. Lipoprotein(a): current perspectives. Curr Vasc Pharmacol 2011;9(6):682–92.
Jin YP, Qin GM, Zhang SZ, Li CJ, Xu G. Clinical evaluation of risk factors for coronary heart disease. Zhonghua Yu Fang Yi Xue Za Zhi 2003;37(2):98–101.
Jürgens G, Taddei-Peters WC, Költringer P, Petek W, Chen Q, Greilberger J, et al. Lipoprotein(a) serum concentration and apolipoprotein(a) phenotype correlate with severity and presence of ischemic cerebrovascular disease. Stroke 1995;26(10):1841–8.
Renistadler SJ, Klug G, Feistritzer HJ, Mayr A, Badar K, Mair J, et al. Relation of plasma adiponectin levels and aortic stiffness after acute ST-segment elevation myocardial infarction. Eur Heart J Acute Cardiovasc Care 2014;3(1):10–7.
Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006;27(19):2300–9.
Vasiljević Z, Stojanović B, Kocev N, Stefanović B, Mrdović I, Ostojić M, et al. [Hospital mortality trend analysis of patients with ST elevation myocardial infarction in the Belgrade area coronary care units]. Srp Arh Celok Lek 2008;136(Suppl 2):84–96.
Tisminetzky M, Coukos JA, McManus DD, Darling CE, Joffe S, Gore J, et al. Decade-long trends in the magnitude, treatment, and outcomes of patients aged 30 to 54 years hospitalized with ST-segment elevation and non-ST-segment elevation myocardial infarction. Am J Cardiol 2014;113(10):1606–10.
Darling CE, Fisher KA, McManus DD, Coles AH, Spencer FA, Gore JM, et al. Survival after hospital discharge for ST-segment elevation and non-ST-segment elevation acute myocardial infarction: a population-based study. Clin Epidemiol 2013;5:229–36.
Das SR, Alexander KP, Chen AY, Powell-Willey TM, Diercks DB, Peterson ED, et al. Impact of body weight and extreme obesity on the presentation, treatment, and in-hospital outcomes of 50,149 patients with ST-segment elevation myocardial infarction results from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol 2011;58(25):2642–50.
Lavie CJ, De Schutter A, Patel DA, Romero-Corral A, Artham SM, Milani RV. Body composition and survival in stable coronary heart disease: impact of lean mass index and body fat in the “obesity paradox”. J Am Coll Cardiol 2012;60(15):1374–80.
Yunyun W, Tong L,Yingwu L, Bojiang L, Yu W, Xiaomin Hu, et al. Analysis of risk factors of ST-segment elevation myocardial infarction in young patients. BMC Cardiovasc Disord 2014;14:179.
Doga LC, Kaul U, Mansoor A. Approach to STEMI and NSTEMI. J Assoc Physicians India 2011;59(Suppl):19–25.
Marrow DA, Braunwald E. Future of Biomarkers in acute coronary syndrome: Moving toward a multi marker strategy. Circulation 2003;108(3):250–2.
El Khoudary SR, Barinas-Mitchell E, White J, Sutton-Tyrrell K, Kuller LH, Curb JD, et al. Adiponectin, systolic blood pressure, and alcohol consumption are associated with more aortic stiffness progression among apparently healthy men. Atherosclerosis 2012;225(2):475–80.
Shojaie M, Sotoodah A, Shafaie G. Is adiponectin associated with acute myocardial infarction in Iranian non obese patients? Lipids Health Dis 2009;8:17.
Dullaart RP, van Pelt LJ, Kwakernaak AJ, Dikkeschei BD, van der Horst IC, Tio RA. Plasma lipoprotein-associated phospholipase A2 mass is elevated in STEMI compared to non-STEMI patients but does not discriminate between myocardial infarction and non-cardiac chest pain. Clin Chim Acta 2013;424:136–40.
Cho JY, Jeong MH, Ahn Y, Hong YJ, park HW, Yoon NS. et al. High Lipoprotein(a) Levels are Associated With Long-Term Adverse Outcomes in Acute Myocardial Infarction Patients in High Killip Classes. Korean Circ J 2010;40(10):491–8.
Kamstrup PR, Benn M, Tybjærg-Hansen A, Nordestgaard BG. Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population. The Copenhagen City Heart Study. Circulation 2008;117(2):176–84.
Nielsen LB, Stender S, Kjeldsen K, Nordestgaard BG. Specific accumulation of lipoprotein(a) in balloon-injured rabbit aorta in vivo. Circ Res1996;78(4):615–26.
Deb A, Caplice NM. Lipoprotein(a): new insights into mechanisms of atherogenesis and thrombosis. Clin Cardiol 2004;27(5):258–64.
Mitsuda T, Uemura Y, Ishii H, Takemoto K, Uchikawa T, Koyasu M, et al. Lipoprotein(a) levels predict adverse vascular events after acute myocardial infarction. Heart Vessels 2016;1–7.
Li L, Zhao H, Zhang X, Wang S, Li C. Association between high-sensitivity C reactive protein/Adiponectin an, Resistin in patients with non-ST elevation acute coronary syndrome. Heart 2011;97(Suppl 3):A145.
Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33(20):2551–67.
Kumar A, Cannon CP. Acute Coronary Syndromes: Diagnosis and Management, Part I. Mayo Clin Proc 2009;84(10):917–38.
Antman EM, Tanasijevic MJ, Thompson B, Schactman M, McCabe CH, Cannon CP, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996;335(18):1342–9.
Ohman EM, Armstrong PW, Christon RH, Granger CB, Katus HA, Hamm CW, et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators. N Engl J Med 1996;335(18):1333–41.
Goodman SG, Steg PG, Eagle KA, Fox KA, López-Sendón J, Montalescot G, et al. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151(3):654–60.